

**EMERGING TECH RESEARCH** 

# **Retail Healthtech**

Q2 2021 VC update

## **Report preview**

The full report is available through the PitchBook Platform.



## **Contents**

Vertical overview	3
Q2 2021 timeline	4
Retail healthtech VC ecosystem market map	5
VC activity	6
Emerging opportunities	13
Mental health applications	14
Gut microbiome	16
Sleep technology	19
Select company highlights	21
Mindstrong	22
Noom	24

Institutional Rese
ANALYSIS
<b>Kaia Colban</b> Analyst, B
DATA
Susan Hu Associate D
Publishing
Designed by Julia Mid
Cover by Julia Midkiff
Published on Septemb

### earch Group

Emerging Technology

ata Analyst

#### lkiff

ber 1, 2021

CONFIDENTIAL. NOT FOR REDISTRIBUTION. PG 2

## Q2 2021 timeline

#### April 13, 2021

DEAL

2

**Tempo**, a smart home gym provider, raises the largest deal tracked among biometric wearables and devices in Q2. With a 2.7x valuation step up, **Tempo**'s \$220.0 million Series C drives its post-money valuation up to \$776.0 million.

#### May 26, 2021

VC DEAL

Akili, a digital therapeutics provider, raises the largest deal tracked within the virtual health segment in Q2-a \$160.0 million Series D. The funds will be used to commercialize its video game treatment. EndeavorRx, which is FDA approved to improve cognitive function in children with attention deficit hyperactivity disorder.

June 16, 2021 23andMe (NASDAQ: ME), traditionally a DTC genetic test provider, goes public as a \$3.5 billion company via a special purpose acquisition company (SPAC). The stock gained 21% on its first day of trading, closing at \$13.32 per share; the stock has since lost all its gains.

EXIT

2

Apr

#### May 25, 2021

**Noom** raises the largest deal tracked in Q2, a \$540.0 million DEAL Series F. Noom, traditionally a weight-loss company, will use the U funding to address more health variables such as stress, anxiety, and sleep.

#### June 7, 2021

Ζ

Apple (NASDAQ: AAPL) announces numerous updates to its health & wellness features. Updates include a walking steadiness biomarker, data sharing capabilities, and a mindfulness application. This demonstrates Big Tech's interest in the healthcare industry.

Jun

## June 9, 2021 Accolade (NASDAQ: ACCD)

EXIT

2

acquires **PlushCare**, a virtual primary care and mental health consultation company, for \$450.0 million. Together, their total addressable market surpasses \$200 billion.<sup>1</sup>

1: "Accolade to Acquire PlushCare," Accolade, April 23, 2021.

30

#### VC ACTIVITY (\$)

\$3.5B Q2 2021 VC deal value

\$8.4B 2021 VC deal value

## \$12.4B

TTM VC deal value

### VC ACTIVITY (#)

92 Q2 2021 VC deal count 266 2021 VC deal count

## 488

TTM VC deal vcount

## **Retail healthtech VC ecosystem market map**

Click to view interactive market map on the PitchBook Platform.

Market map is a representative overview of venture-backed or growth-stage providers in each segment. Companies listed have received venture capital or other notable private investments.



**Biometric wearables & devices** 

Biometric monitoring wearables

Remote patient monitoring (RPM) tools

**Dietary supplements** Vitamins & supplements ALOHA care/of katefarms 🔅 spoonfulone. RILLETPROOF

Creative



MANUAL

CONFIDENTIAL, NOT FOR REDISTRIBUTION, PG 5

## VC activity

Retail healthtech VC deal value dropped relative to Q1, with \$3.5 billion invested across 92 deals in Q2. The decline in deal value was driven by a roughly 60% funding drop in personalized medicine and testing deals relative to a very active Q1. However, Q2 deal value was only slightly down from Q1 2021's, which set a record high. The virtual health segment was the only other segment to experience a decline in deal value—\$1.2 billion in Q2 versus \$1.8 billion in Q1—though it remained the top-funded segment across retail health & wellness tech. Mobile & digital health was the second top-funded segment in the quarter, with \$1.2 billion raised across 10 deals. All five segments experienced a decrease in deal count, except dietary supplements, which remained flat with eight deals.

Driven by the 10 VC mega-deals (deals sized at \$100 million or larger), median deal size doubled to \$52.2 million in Q2. These mega-deals accounted for 60% of disclosed deal value. Noom, Fiture, Gympass, and Tempo raised deals over \$200 million. All four startups develop fitness/ nutrition-related solutions. We believe COVID-19 heightened the focus on preventative health among individuals and employers, thus increasing market opportunity for startups in this space. Noom's \$540.0 million Series F raised its post-money valuation to \$4.2 billion, thereby making it the second-highest valued company tracked within retail healthtech.

VC exit activity more than doubled in disclosed deal value to \$1.7 billion, though deal count decreased from 14 to 10 from Q1 to Q2-consisting of six M&A transactions, three IPOs, and one leveraged buyout (LBO). 23andMe, a genomic test provider that now aims to develop therapeutic drugs, went public on the Nasdag at a \$3.5 billion post-money valuation. The stock rose 21% on its first day of trading but has since continually fallen. We believe **23andMe** may struggle to increase revenues in the near term as developing drugs is a costly and lengthy process. In the M&A space, Accolade acquired telemedicine platform PlushCare for \$450.0 million.





Source: PitchBook | Geography: Global | \*As of June 30, 2021

Source: PitchBook | Geography: Global | \*As of June 30, 2021

## VC ACTIVITY

#### Figure 7.

## Key retail healthtech early-stage VC deals

COMPANY	CLOSE DATE	SUBSEGMENT	STAGE	DEAL SIZE (\$M)	LEAD INVESTOR(S)	VALUATION STEP- UP*
Fiture Technology	April 14, 2021	Fitness applications	Series B	\$300.0	All-Stars Investment	N/A
Medically Home	May 13, 2021	Telemedicine	Early-stage VC	\$100.0	N/A	N/A
Tesseract Health	April 20, 2021	Remote patient monitoring (RPM)	Series B	\$80.0	N/A	N/A
Brightline	May 17, 2021	Digital therapeutics	Series B	\$72.0	GV	3.1x
miDiagnostics	April 30, 2021	Ad-hoc personalized testing	Angel	\$69.3	N/A	N/A
Wheel	May 19, 2021	Telemedicine	Series B	\$50.0	Lightspeed Venture Partners	N/A
Proximie	April 21, 2021	Telemedicine	Series B	\$35.9	F-Prime Capital	2.0x
The Nue Co	May 25, 2021	Vitamins & supplements	Series B	\$35.8	N/A	1.6x
Ergatta	April 28, 2021	Smart devices	Series A	\$29.7	Advance Venture Partners	11.6x
Paceline	June 7, 2021	Smart devices	Series A	\$29.6	Acrew Capital	6.9x

Source: PitchBook | Geography: Global | \*As of June 30, 2021

## **VC ACTIVITY**

#### Figure 10.

## Key strategic acquirers of retail healthtech companies since 2018\*

INVESTOR	DEAL COUNT*	INVESTOR TYPE
Teladoc Health	3	Corporation
Invitae	3	Corporation
HealthHero	2	Corporation
WELL Health Technologies	2	Corporation
Everlywell	2	VC-backed company
SOC Telemed	2	Corporation
InTouch Health	2	Corporation
Amwell	2	Corporation

Source: PitchBook | Geography: Global | \*As of June 30, 2021

#### Figure 11.

## Top VC investors in retail healthtech companies since 2017\*

INVESTOR	DEAL COUNT*	INVESTOR TYPE
SOSV	46	VC
Khosla Ventures	41	VC
True Ventures	36	VC
Social Capital	28	VC
Founders Fund	26	VC
Kleiner Perkins	25	VC
Sequoia Capital	24	VC
General Catalyst	22	VC
Enterprise Ireland	21	VC
GV	21	CVC

Source: PitchBook | Geography: Global | \*As of June 30, 2021

### SELECT COMPANY HIGHLIGHT | MINDSTRONG

## mindstrong

Founded
2014

Total raised \$159.9M

Employees 149

Valuation \$675.0M

#### **Overview**

**Mindstrong** provides virtual therapy and psychiatry to patients with serious mental illness (SMI). SMI is defined as a mental, behavioral, or emotional disorder that substantially interferes with one or more life activity. Its platform operates as a mobile application for patients and passively monitors patient phone activity to measure cognitive biomarkers, providing passive input to active therapy. **Mindstrong** believes a correlation exists between phone usage and mental health and is trying to determine how passive phone utilization data can signal declines in mental health. Unlike many telemedicine providers, **Mindstrong** is not just a link between doctors and patients. Rather, it employs the providers and offers the services directly, thereby creating safe, continuous care for patients. By providing the care itself, **Mindstrong** can utilize passively collected data in care to give more efficient, personalized, and holistic care. For example, **Mindstrong** providers rank patients on the clinical global impression scale (CGIS) after each session. The platform also hypothesizes the patient's symptom severity based on phone usage. By comparing the two, **Mindstrong** has gathered early signals correlating phone usage to symptom severity.

### Competitors

**Mindstrong** focuses on SMI, while most competitors hone in on milder forms of mental illness. Keeping patients with SMI engaged is more difficult and thus often avoided by other digital health providers. However, some may argue patients with SMI are likely to need in-person care. **Mindstrong** will connect patients with in-person providers but believes virtual care can help keep patients engaged and improve patient outcomes. Furthermore, provider shortage makes it difficult for patients in rural areas to receive in-person care. While telemedicine connectors—those that connect patients to providers but do not provide services—can increase access to providers, they are often not designed to keep patients engaged and do not guarantee quality of care.

### Leadership

Focused on bringing innovation-minded leaders from various sectors to merge technology with patient-first personalized care, **Mindstrong**'s leadership team has been recently overhauled. The team is led by CEO Michelle Wagner.

## SELECT COMPANY HIGHLIGHT | MINDSTRONG

### Outlook

We believe increasing unification will emerge between therapy-first and self-management technology. Therapy-first providers such as **Mindstrong** will need to acquire or develop technology to keep patients engaged between sessions, and self-management technology providers will need to develop ways for consumers to gain access to professionals when they need more serious clinical care.

As data proves behavioral healthcare can reduce the total cost of care, payers will be incentivized to partner with behavioral care providers. Better mental healthcare is likely to reduce physical healthcare costs as patients take better care of their physical health when mentally healthy. However, proving cost reduction will require longitudinal studies.

#### Figure 16.

### **Financing history**

SERIES C	SERIES B	SERIES A
May 21, 2020	December 21, 2018	February 27, 2017
Raised to date: \$159.6M	Raised to date: \$59.9M	Raised to date: \$14.4M
Post-money valuation:	Post-money valuation:	Post-money valuation:
\$675.0M	\$200.0M	\$34.4M

CONFIDENTIAL, NOT FOR REDISTRIBUTION, PG 23



## About PitchBook Emerging Tech Research

## Independent, objective, and timely market intel

As the private markets continue to grow in complexity and competition, it's essential for investors to understand the industries, sectors and companies driving the asset class.

Our Emerging Tech Research provides detailed analysis of nascent tech sectors so you can better navigate the changing markets you operate in—and pursue new opportunities with confidence.

©2021 by PitchBook Data, Inc. All rights reserved. No part of this publication may be reproduced in any form or by any means—graphic, electronic, or mechanical, including photocopying, recording, taping, and information storage and retrieval systems—without the express written permission of PitchBook Data, Inc. Contents are based on information from sources believed to be reliable, but accuracy and completeness cannot be guaranteed. Nothing herein should be construed as any past, current or future recommendation to buy or sell any security or an offer to sell, or a solicitation of an offer to buy any security. This material does not purport to contain all of the information that a prospective investor may wish to consider and is not to be relied upon as such or used in substitution for the exercise of independent judgment.

John Gabbert Founder, CEO Nizar Tarhuni Senior Director, Institutional Research & Editorial Paul Condra Head of Emerging Technology Research

### **Additional research**

Agtech Alex Frederick alex.frederick@pitchbook.com

Artificial Intelligence & Machine Learning Brendan Burke brendan.burke@pitchbook.com

Cloudtech & DevOps Paul Condra paul.condra@pitchbook.com

Fintech Robert Le robert.le@pitchbook.com

Foodtech Alex Frederick alex.frederick@pitchbook.com

Healthtech Kaia Colban kaia.colban@pitchbook.com Information Security Brendan Burke brendan.burke@pitchbook.com

Insurtech Robert Le robert.le@pitchbook.com

Internet of Things (IoT) Brendan Burke brendan.burke@pitchbook.com

Mobility Tech Asad Hussain asad.hussain@pitchbook.com

Supply Chain Tech Asad Hussain asad.hussain@pitchbook.com